Navigation Links
Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
Date:4/16/2009

STOCKHOLM, Sweden, April 16 /PRNewswire/ -- Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that it has signed two distributor agreements - with Asbach Medical Products GmbH and with Oxford Biosystems Ltd.

Carina Schmidt, CEO of Athera, said "We are very excited about the opportunities these agreements present to Athera. They will allow us to reach a large number of customers in Germany and UK and will support further development of the broader clinical utility of our new CVD biomarker. We are looking forward to work with the experienced team in Asbach Medical Products and Oxford Biosystems."

High levels of IgM antibodies against phosphorylcholine (anti-PC) has been shown to predict less atherosclerosis development in hypertensive patients after a five-year follow up. However, in 2008 data indicating that low anti-PC levels predict an increased risk of CVD were presented. One study included myocardial infarction (MI) patients and suggested that anti-PC measurements could be used to predict the likelihood of secondary CVD events up to six months after an initial event. This has since been followed up with another study involving over 1000 ACS patients. The product, CVDefine(R), was introduced last year and provides an easy-to-use ELISA kit (CE-marked) for quantitative analysis of anti-PC in human blood.

About Athera Biotechnologies

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is part of the Karolinska Development AB (publ) portfolio.

In 2008 Athera started a collaboration with Dyax Corp. (NASDAQ: DYAX) to discover and develop antibodies for treatment of cardiovascular inflammation. The therapy is based on phosphorylcholine (PC) and low levels of antibodies to PC in human serum have been linked with an increased risk of developing CVD. Athera is also a major partner in the highly ranked EU-project CVDIMMUNE lead by Karolinska Institutet. The project involves 10 partners, also including Phadia GmbH, TNO, Johannes Gutenberg-University Mainz and Leiden University Medical Center.

   http://www.athera.se
    Contact:
    Carina Schmidt, CEO, Phone: +46-705525115, Mail: c.schmidt@athera.se
    About Asbach Medical Products

The company was founded in 2003 within the Technologie Park Neckar-Odenwald by Thomas Bossmann, a former Manager of Diagnostic Products Corporation and Diagnostic Systems Laboratories Germany, having long experience in the field. The target of Asbach Medical Products is distribution of high quality in vitro diagnostics.

   http://www.amp-asbach.com
    Contact:
    Thomas Bossmann, CEO, Mail: t.bossmann@amp-asbach.com
    About Oxford Biosystems

Oxford Biosystems is a supplier of in vitro - diagnostics and immunochemicals for routine and research. Specialized in new innovative immunoassays and other analytical methods e.g. HPLC, PCR, in different areas of medical laboratory diagnostics, medical research and industrial laboratories.

http://www.oxfordbiosystems.com

Contact:

John Coombes, CEO, Mail: jcoombes@oxfordbiosystems.com


'/>"/>
SOURCE Athera Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
2. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
3. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
6. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
7. New Generation Biofuels Signs Sales Contract with Catoctin Mountain Growers to Supply up to 370,000 gallons of Renewable Biofuel
8. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
9. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
10. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
11. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and BEIJING , Nov. 30, 2016 ... provider of genomic services and solutions with cutting edge ... it has completed a USD $75 Million [515 Million ... Ltd.,s CMB International Capital Management ( Shenzhen ... Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
(Date:11/30/2016)... Park, NC (PRWEB) , ... November 30, 2016 ... ... company engaged in the development of a new orally administered treatment for Alzheimer’s ... and neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
Breaking Biology Technology:
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
Breaking Biology News(10 mins):